Background: Biliary tract cancers (BTCs) represent a heterogeneous group of aggressive solid tumors with limited therapeutic options, and include gallbladder cancer (GBC), ampulla of Vater cancer (AVC), intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA). Methods & Results: In the current review, we will discuss recent results of clinical trials testing targeted therapies in BRAF-mutant BTCs, with a particular focus on the recently published Phase II ROAR trial and ongoing active and recruiting clinical trials. Conclusions: Although the extended use of molecular profiling has paved the way toward a new era in BTC management, targeted therapies are limited to iCCA so far, and the prognosis of patients with metastatic disease has substantially not changed in the last decade. In this discouraging scenario, BRAF inhibition is currently emerging as a novel treatment option in patients harboring BRAF mutations.

Rizzo A., Federico A.D., Ricci A.D., Frega G., Palloni A., Pagani R., et al. (2020). Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. CANCER CONTROL, 27(1), 1-8 [10.1177/1073274820983013].

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges

Rizzo A.;Ricci A. D.;Frega G.;Palloni A.;Pagani R.;Tavolari S.;Brandi G.
2020

Abstract

Background: Biliary tract cancers (BTCs) represent a heterogeneous group of aggressive solid tumors with limited therapeutic options, and include gallbladder cancer (GBC), ampulla of Vater cancer (AVC), intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA). Methods & Results: In the current review, we will discuss recent results of clinical trials testing targeted therapies in BRAF-mutant BTCs, with a particular focus on the recently published Phase II ROAR trial and ongoing active and recruiting clinical trials. Conclusions: Although the extended use of molecular profiling has paved the way toward a new era in BTC management, targeted therapies are limited to iCCA so far, and the prognosis of patients with metastatic disease has substantially not changed in the last decade. In this discouraging scenario, BRAF inhibition is currently emerging as a novel treatment option in patients harboring BRAF mutations.
2020
Rizzo A., Federico A.D., Ricci A.D., Frega G., Palloni A., Pagani R., et al. (2020). Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. CANCER CONTROL, 27(1), 1-8 [10.1177/1073274820983013].
Rizzo A.; Federico A.D.; Ricci A.D.; Frega G.; Palloni A.; Pagani R.; Tavolari S.; Marco M.D.; Brandi G.
File in questo prodotto:
File Dimensione Formato  
Targeting BRAF-Mutant Biliary.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 371.88 kB
Formato Adobe PDF
371.88 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/875762
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 17
social impact